Merrimack Pharmaceuticals, Inc.

Jeffrey David Kearns

Ulrik Bjerl Nielsen

Raghida Bukhalid

Alexey Alexandrovich Lugovskoy

Michael Feldhaus

Eric Krauland

Neeraj Kohli

Anne Richard

Beni B Wolf

Anne King

Shannon Werner

Anti-EGFR antibodies, therapeutic compositions comprising combinations of anti-EGFR antibodies, as well as methods for using such antibodies and compositions to treat EGFR-related disorders (e.g., cancers), are disclosed.

Antibodies against epidermal growth factor receptor (EGFR) and uses thereof

Methods for optimizing a therapeutic response in a patient (e.g., a cancer patient) to an anti-EGFR therapy, and methods for preventing or ameliorating infusion reactions in a patient receiving an anti-EGFR therapy are disclosed.

Dosage and administration of anti-EGFR therapeutics

Disclosed are pharmaceutical preparations for, and methods for determining, appropriate and effective treatment with therapeutic agents comprising a single species of anti-EGFR monoclonal antibody or therapeutic agents comprising a plurality of species of such antibodies, as well as kits useful for making such determinations.

Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies

Growing community of inventors

Arlington, MA, United States of America

Jeffrey David Kearns